Vico Therapeutics B.V. is a clinical-stage genetic medicines company advancing therapies for severe neurodegenerative diseases. Its lead program, VO659, is in a Phase 1/2a clinical study in patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease. The company is developing a portfolio of novel antisense oligonucleotides aimed at diseases with no current disease-modifying treatments. Recent financing is intended to bolster its clinical programs and support further development of its pipeline. The articles note ongoing clinical development and a completed Series B financing round totaling €65.8 million ($70.7 million) to support these activities. Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA‑modulating therapies for severe neurological diseases. Its lead product candidate, VO659, is in a Phase 1/2a multi-center, open‑label basket trial in patients with spinocerebellar ataxia type 3 (SCA3), type 1 (SCA1) and early manifest Huntington's disease (HD). The trial is assessing safety and tolerability of multiple ascending intrathecal doses; the first patient was dosed in April 2023. Vico’s platform designs fit‑for‑purpose ASOs that target genetic neurological diseases, and VO659 is described as the only ASO in the clinic that targets the underlying CAG repeat expansions responsible for all nine known polyglutamine diseases. The company plans to use the new funding to advance VO659 through the ongoing clinical study and to support discovery and research to expand its pipeline into other genetic neurological diseases. Financially, Vico announced a $60 million (€54 million) Series B to support overall company operations and clinical development. Vico Therapeutics develops RNA‑modulating therapies, notably an antisense oligonucleotide (AON) platform targeting expanded CAG trinucleotide repeats that produce toxic polyglutamine stretches. Its lead AON asset is directed at polyQ neurodegenerative disorders including Spinocerebellar Ataxia type 1 and 3 (SCA1, SCA3) and Huntington’s disease (HD). The company also operates an early‑discovery RNA editing platform focused on Rett syndrome. Vico plans to use the Series A proceeds to advance its late preclinical AON programs into first‑in‑human clinical trials in late 2021. The company raised $31M in the Series A financing announced July 29, 2020, improving its runway to support those clinical plans. Vico was founded in 2019 and is based in Leiden, Netherlands.

Total raised

$103M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2024